Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(2.25)
# 2,763
Out of 5,241 analysts
54
Total ratings
31.37%
Success rate
3.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALEC Alector | Upgrades: Overweight | n/a | $2.12 | - | 7 | Apr 15, 2026 | |
| CRVO CervoMed | Initiates: Overweight | n/a | $3.04 | - | 1 | Dec 18, 2025 | |
| NVAX Novavax | Initiates: Overweight | $18 | $8.93 | +101.57% | 1 | Oct 24, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Neutral | n/a | $0.8065 | - | 5 | Jul 7, 2025 | |
| DRUG Bright Minds Biosciences | Assumes: Overweight | n/a | $75.00 | - | 1 | Jul 2, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $107 → $100 | $34.35 | +191.12% | 8 | May 7, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Overweight | n/a | $3.53 | - | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $7.03 | - | 6 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Reinstates: Neutral | n/a | $1.18 | - | 5 | Mar 4, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $26.76 | - | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.96 | - | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.26 | - | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $83.60 | - | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $3.24 | +54.32% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $2.18 | +496.33% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $19.90 | -59.80% | 1 | Mar 20, 2023 |
Alector
Apr 15, 2026
Upgrades: Overweight
Price Target: n/a
Current: $2.12
Upside: -
CervoMed
Dec 18, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.04
Upside: -
Novavax
Oct 24, 2025
Initiates: Overweight
Price Target: $18
Current: $8.93
Upside: +101.57%
Jasper Therapeutics
Jul 7, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.8065
Upside: -
Bright Minds Biosciences
Jul 2, 2025
Assumes: Overweight
Price Target: n/a
Current: $75.00
Upside: -
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107 → $100
Current: $34.35
Upside: +191.12%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.53
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.03
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.18
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $26.76
Upside: -
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.96
Upside: -
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.26
Upside: -
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $83.60
Upside: -
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $3.24
Upside: +54.32%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $2.18
Upside: +496.33%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $19.90
Upside: -59.80%